Staphylococcus aureus is a bacterial pathogen responsible for significant morbidity, mortality, and excess healthcare cost worldwide. Treatment of S. aureus infection has become difficult due to the prevalence of antibiotic resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA). 

The inventors have identified novel vaccine candidates which elicit robust humoral responses and effectively reduced the acquisition and colonization of S. aureus,  including MRSA in vivo. A preventive vaccine or treatment therapy based on this technology represents a major clinical advance and would address a multibillion dollar market opportunity.